KalVista Pharmaceuticals, Inc. Common Stock (KALV)
KalVista Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel, oral protease inhibitors for the treatment of hereditary angioedema (HAE) and other medical conditions. Founded in 2009 and based in the United States, the company aims to advance targeted therapies to improve patient outcomes through innovative drug development and clinical programs.
Company News
KalVista Pharmaceuticals launched EKTERLY, its first oral treatment for hereditary angioedema, generating $1.4 million in Q1 FY2026 revenue. The launch was accompanied by increased commercialization expenses and a widened net loss, reflecting the company's transition to commercial operations.
The FDA approved Ionis Pharmaceuticals' Dawnzera, the first RNA-targeted medicine for preventing hereditary angioedema (HAE) attacks in patients 12 and older, demonstrating significant attack rate reduction in clinical trials.
The angioedema treatment market is expected to grow due to the rising prevalence of allergic conditions and increasing awareness of hereditary angioedema (HAE). The pipeline analysis shows over 15 companies are developing 20+ angioedema drugs, with promising therapies in different clinical trial phases.
Here is how Amneal Pharmaceuticals (AMRX) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.
KalVista is positioned to disrupt the HAE treatment landscape with its oral therapy, sebetralsta. Read why I recommend a speculative Buy for KALV stock.